Zobrazeno 1 - 10
of 26
pro vyhledávání: '"Robert D. Warren"'
Autor:
Mahsa Mohebtash, Tianmin Wu, Matthew Blackburn, Ming Tan, Robert D. Warren, Christopher Gallagher, Paula R. Pohlmann, Asma Dilawari, Maysa M. Abu-Khalaf, Olwen Hahn, Ayesha N. Shajahan-Haq, Shruti Tiwari, Rebecca Zhuo, Filipa Lynce, Ami Chitalia, Claudine Isaacs
Publikováno v:
Cancer. 127:3622-3630
Background Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors, including palbociclib, are approved to treat hormone receptor (HR)-positive/human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC) and are associated with hema
Autor:
Matthew Blackburn, Claudine Isaacs, Ayesha N. Shajahan-Haq, Christopher Gallagher, Olwen Hahn, Filipa Lynce, Paula R. Pohlmann, Ming Tan, Ami Chitalia, Asma Dilawari, Maysa M. Abu-Khalaf, Mahsa Mohebtash, Robert D. Warren, Tianmin Wu, Shruti Tiwari, Rebecca Zhuo
Publikováno v:
Cancer Research. 80:P1-19
Background: There are significant racial disparities in breast cancer outcomes between African American women (AAW) and Caucasian women (CW) in the US. It has been reported that AAW have more chemotherapy dose reductions than CW which results in wors
Autor:
P. Timothee, Raquel Nunes, Karen L. Smith, Monvadi B. Srichai, Ming Tony Tan, Chau T. Dang, Claudine Isaacs, P. Herbolsheimer, Ayesha N. Shajahan-Haq, Christopher Gallagher, Sandra M. Swain, Mark Hofmeyer, Ana Barac, X. Geng, Anthony F. Yu, A. Cunningham, Robert D. Warren, Filipa Lynce, Federico M. Asch, Paula R. Pohlmann
Publikováno v:
Breast Cancer Research and Treatment
Purpose HER2-targeted therapies have substantially improved the outcome of patients with breast cancer, however, they can be associated with cardiac toxicity. Guidelines recommend holding HER2-targeted therapies until resolution of cardiac dysfunctio
Autor:
Robert D. Warren, Chau T. Dang, Federico M. Asch, Claudine Isaacs, Monvadi B. Srichai, Raquel Nunes, Anthony F. Yu, Paula R. Pohlmann, Katia E. Khoury, Ming Tan, P. Herbolsheimer, Xue Geng, Karen L. Smith, Christopher Gallagher, Mark Hofmeyer, Filipa Lynce, Sandra M. Swain, Ana Barac
Publikováno v:
Breast Cancer Res Treat
PURPOSE: HER2-targeted therapies are associated with cardiotoxicity which is usually asymptomatic and reversible. We report the updated cardiac safety assessment of patients with compromised heart function receiving HER2-targeted therapy for breast c
Autor:
Claudine Isaacs, Bhaskar Kallakury, Larissa A. Korde, Brandy M. Heckman-Stoddard, Margaret E. Gatti-Mays, Claudia E. Galbo, James F. Reynolds, Ann Gallagher, Robert D. Warren, Andrea Singer, Erini Makariou, David Venzon, Jennifer Eng-Wong
Publikováno v:
Cancer Prevention Research. 9:225-233
This phase II trial evaluated clinical markers of efficacy and safety of exemestane in postmenopausal women at increased risk for breast cancer. Postmenopausal women (n = 42) at risk for invasive breast cancer received 25 mg exemestane daily for 2 ye
Autor:
Claudine Isaacs, Karen L. Smith, Lynette Wray, Nawar Shara, Filipa Lynce, Madeline P. Nardacci, P. Herbolsheimer, Mihriye Mete, Sandra M. Swain, Federico M. Asch, Ana Barac, Robert D. Warren, Beth N. Peshkin, Raquel Nunes
Publikováno v:
Breast Cancer Research and Treatment. 155:285-293
Animal data suggest that defects in BRCA1/2 genes significantly increase the risk of heart failure and mortality in mice exposed to doxorubicine. Women with BRCA1/2 mutations who develop breast cancer (BC) may receive anthracyclines but their risk of
Autor:
Robert D. Warren, Margaret E. Gatti-Mays, Filipa Lynce, Paula R. Pohlmann, Christopher Gallagher, Sandra M. Swain, Hongkun Wang, D Graham, Jeffrey Schlom, Renee N. Donahue, Asma Dilawari, Katia E. Khoury, Claudine Isaacs
Publikováno v:
Cancer Research. 79:OT3-04
Background: Long-term follow-up of neoadjuvant studies demonstrates poor clinical outcomes in patients with TNBC who do not achieve pathologic complete response, with only 35% remaining free of recurrence at 10 years. The addition of adjuvant capecit
Autor:
Lynette Wray, Mihriye Mete, Claudine Isaacs, Karen L. Smith, Raquel Nunes, Madeline Nardacci, Filipa Lynce, P. Herbolsheimer, Robert D. Warren, Sandra M. Swain, Ana Barac
Publikováno v:
Cancer Research. 75:P1-03
Introduction: Animal data suggest that cardiac-specific loss of BRCA1/2 genes leads to increased cardiac dysfunction in the setting of stressors such as ischemia or anthra chemotherapy (CT). Women with BRCA1/2 mutations who develop BC may receive ant
Autor:
Ann Gallagher, Claudine Isaacs, Philip Cohen, Robert D. Warren, Bvs Kallakury, Margaret E. Gatti-Mays, E Makariou, E Permaul, David Venzon, Jennifer Eng-Wong
Publikováno v:
Cancer Research. 72:P1-09
Background: Aromatase inhibitors (AI) are effective for breast cancer risk reduction in postmenopausal women. TFF1, also known as pS2, is an estrogen response gene present in normal mammary tissue with increased expression in estrogen receptor positi
Autor:
Larissa A. Korde, Claudine Isaacs, Philip Cohen, Ann Gallagher, M Gatti, David Venzon, Robert D. Warren, Jennifer Eng-Wong, JoAnne Zujewski
Publikováno v:
Cancer Research. 71:P3-11
Background: Aromatase inhibitors are effective for breast cancer prevention in postmenopausal women. In the recent MAP.3 study, exemestane significantly reduced invasive breast cancer in postmenopausal women with an elevated risk of developing breast